日本醫藥物流市場：依類型、任務、組成、應用、營運、地區、機會及預測，2019-2033

受不斷成長的藥品需求、複雜的藥品供應鏈以及嚴格的監管要求的推動，日本醫藥物流市場預計將從2025年的532萬美元成長到2033年的843萬美元，預測期內（2026-2033年）的年複合成長率為5.93%。日本醫藥物流市場正處於精準化、監管和創新的十字路口。隨著日本對高價值治療藥物（包括生物製藥、特殊藥物和個人化藥物）的需求日益成長，確保安全、合規和及時交付的壓力比以往任何時候都更加重要。隨著人口老化和嚴格的監管要求，日本的物流合作夥伴不僅需要交付藥品，還需要確保治療的完整性，直到最後一公里。

自新冠疫情爆發以來，日本加快了對冷鏈基礎設施、自動化和即時監控技術的投資，將物流從後端成本中心轉變為實現醫療資源可及性的一線。在這個攝氏2度的溫差就可能使貨物失去價值的產業，溫度偏差、運輸延誤和人為錯誤如今已是不可接受的。

例如，2023年9月，Takeda Pharmaceutical與Mitsubishi Logistics和 JR Freight合作，試行了藥品溫控鐵路運輸解決方案。這項措施代表了傳統陸上運輸方式的重大轉變，在維持嚴格符合GDP標準的溫控要求並降低振動風險的同時，將二氧化碳排放量減少了60%。這是日本首個使用鐵路的藥品物流系統。

目錄

第1章 專案範圍與定義

第2章 研究方法

第3章 美國關稅的影響

第4章 執行摘要

第5章 客戶之聲

• 公司經驗與專業知識
• 基礎設施與技術
• 全球影響力與網路
• 風險管理與保險

第6章 2019-2033年日本醫藥流市場展望

• 市場規模分析與預測
  • 依價值
• 市場佔有率分析與預測
  • 依類型
    • 冷鏈物流
    • 非冷鏈物流
  • 依操作
    • 揀選
    • 儲存
    • 檢索系統
    • 處理系統
  • 依組件
    • 儲存
    • 運輸
    • 監控組件
  • 依應用
    • 化學品和製藥
    • 生物製藥
    • 特種藥品
  • 依操作
    • 海運
    • 公路
    • 鐵路
    • 空運
    • 倉儲和服務
  • 依地區
    • 北部
    • 中部
    • 南部
  • 各公司市場佔有率分析（前五名及其他 - 價值導向，2025年）
• 2025年市場地圖分析
  • 依類型
  • 依操作
  • 依組件
  • 依應用
  • 依操作
  • 依地區

第7章 需求與供給分析

第8章 價值鏈分析

第9章 波特五力分析

第10章 PESTLE 分析

第11章 市場動態

• 市場驅動因素
• 市場挑戰

第12章 市場趨勢與發展

第13章 政策與監理情勢

第14章 個案研究

第15章 競爭格局

• 五大市場領導者競賽矩陣
• 五大公司SWOT分析
• 市場十大主要參與者情勢
  • AP MOLLER-MAERSK A/S
  • CEVA Logistics SA
  • Nippon Express Co., Ltd.
  • Logisteed Ltd.
  • Kintetsu World Express, Inc.
  • Yamato Transport Co., Ltd.
  • Sagawa Express Co., Ltd.
  • Yusen Logistics Co., Ltd.
  • Mitsubishi Logistics Corporation
  • DHL International GmbH

第16章 策略建議

第17章 關於調查公司/免責聲明

Japan pharmaceutical logistics market is projected to witness a CAGR of 5.93% during the forecast period FY2026-FY2033, growing from USD 5.32 million in FY2025 to USD 8.43 million in FY2033 due to growth in pharmaceutical demand, increasing complexity of pharmaceutical supply chains, and stringent regulatory requirements. Japan pharmaceutical logistics market stands at the intersection of precision, regulation, and innovation. As the country faces a rising demand for high-value therapeutics, including biopharma, specialty drugs, and personalized medicine, the pressure to ensure safe, compliant, and timely delivery is more critical than ever. With Japan's aging population and strict regulatory requirements, logistics partners are not just expected to deliver, they are also expected to preserve therapeutic integrity down to the last kilometer.

Post-COVID, the country has accelerated investments in cold chain infrastructure, automation, and real-time monitoring technologies, transforming logistics from a back-end cost center into a front-line enabler of healthcare access. Temperature excursions, transit delays, and manual errors are now unacceptable in an industry where 2 degrees Celsius fluctuation can render a shipment worthless.

For instance, in September 2023, Takeda Pharmaceutical partnered with Mitsubishi Logistics and JR Freight to pilot a temperature-controlled rail transport solution for pharmaceuticals. This initiative marked a significant shift from conventional road methods, achieving a 60% reduction in CO2 emissions while maintaining strict GDP-compliant temperature control and mitigating vibration risks, representing the first rail-based pharmaceutical logistics system of its kind in Japan.

Surge in Cold Chain Logistics for Biopharma and Vaccines Fuels Market Growth

Japan's biopharmaceutical sector has expanded rapidly, from monoclonal antibodies to mRNA-based treatments, and these drugs require stable cold chain environments to maintain efficacy. This has triggered a nationwide upgrade in temperature-controlled logistics.

In November 2023, Bushu Pharmaceuticals Ltd. opened the Soka Packaging Center, its 5th base in Japan, inside Prologis Park Soka. This state-of-the-art facility, featuring advanced ecological and safety technologies, offers extensive storage and packaging services for biological and regenerative medical products. The center's capabilities include storing 1,671 pallets at 2-8 degrees Celsius and providing easy access to refrigerated storage from truck berths. This expansion helps Bushu Pharma meet the growing demand for pharmaceutical medicines by ensuring optimal cold storage supply chain operations, contributing to Japan's cold chain logistics market's growth through enhanced efficiency, technology adoption, and ecological sustainability.

In March 2024, Yusen Logistics Co., Ltd. received CEIV Pharma recertification for its Narita International Airport facility as of March 13, 2024. The Narita Healthcare Terminal, opened in 2023, is now certified for pharmaceutical handling and operates in full compliance with Good Distribution Practice (GDP). The facility features advanced temperature controls, supporting pharmaceutical cargo at -20 degrees Celsius, +5 degrees Celsius, and +20 degrees Celsius, to accommodate a wide range of temperature-sensitive medicines.

Hospital-Focused Distribution and Urban Last-Mile Innovation to Shape the Market

Urban healthcare facilities in Japan, especially in Tokyo and Osaka, require strict delivery SLAs for specialty drugs, blood products, and urgent-care items. To meet these demands, logistics companies are innovating last-mile solutions suited for dense urban geographies. Urban-centric innovation in healthcare logistics is becoming a key differentiator in provider partnerships and SLA bidding.

For example, in June 2024, CONCOR (Container Corporation of India Ltd.) and Innovation Thru Energy (ITE), Japan, teamed up to introduce ice battery technology in containers for temperature-sensitive cargo, eliminating the need for diesel generators and maintaining freshness for up to 72 hours. This environmentally friendly solution reduces CO2 emissions by 70-80% and enhances the efficiency of cold chain logistics.

Dominance of Specialized Pharma in Logistics Demand

In Japan, specialized pharmaceuticals, including oncology drugs, orphan disease treatments, biosimilars, and advanced therapy medicinal products (ATMPs) such as cell and gene therapies, are rapidly becoming the most logistics-intensive and commercially valuable segment of pharmaceutical logistics. As Japan's aging population drives a rise in complex, chronic, and rare conditions, the healthcare system is moving toward precision therapies that require strict temperature controls, tighter delivery windows, and near-zero error tolerance. These products often carry short shelf lives, high unit value, and sensitivity to vibration or light, making them especially dependent on specialized logistics networks.

In August 2023, Mitsubishi Logistics Corporation responded to this trend by enhancing its biopharma transport suite with a cloud-integrated logistics visibility platform. The system enables pharmaceutical clients to monitor real-time shipment conditions across storage hubs, roadways, and hospital endpoints, with support for 2 degrees Celsius -8 degrees Celsius, -20 degrees Celsius, and ultra-cold chain below -70 degrees Celsius specifications.

Meanwhile, in February 2025, Essential Pharma Limited ("Essential Pharma") and Clinigen Group plc ("Clinigen") announced an expansion of their JAPAC collaboration to enhance patient access to four therapies in Japan and Korea and strengthen their joint market presence in the region. The expanded partnership includes new market authorisation transfers and exclusive distribution agreements. Building on their 2024 agreement for IOPIDINE (apraclonidine) in Korea, the companies have now extended this arrangement to Japan.

Impact of U.S. Tariffs on Japan Pharmaceutical Logistics Market

U.S. tariffs on pharmaceutical ingredients and packaging supplies-especially those sourced from China and rerouted via U.S. suppliers-have caused upstream pricing volatility. Japanese pharmaceutical manufacturers have had to adapt by sourcing APIs and sterile packaging from alternate regions (e.g., India, Europe), adding pressure on logistics timelines and import scheduling.

To avoid tariff-induced bottlenecks, Japanese logistics firms have re-routed critical pharma shipments away from U.S. transshipment hubs, especially for high-value biopharmaceuticals. This shift has led to increased reliance on regional air cargo routes (via Incheon, Singapore, or Dubai), changing the way 3PLs and 4PLs structure cold chain handoffs and storage.

Higher import costs and trade friction have incentivized Japanese pharma companies to localize more of their logistics infrastructure - investing in domestic GDP-certified cold storage, regional fulfillment hubs, and automated handling systems. This is especially true for firms distributing to hospitals, where lead time and compliance are critical.

Key Players Landscape and Outlook

Japan pharmaceutical logistics market is led by a mix of domestic giants and global specialists. Companies offer end-to-end cold chain, GDP-certified storage, and hospital delivery across all prefectures. Whereas, Yusen Logistics and Sagawa Express are rapidly digitizing operations with IoT and temperature-mapping solutions tailored to Japanese geography. International players provide value in air-sea integration and biosecure customs clearance. Logisteed and Kintetsu World Express are developing niche services in research sample handling and biopharma packaging. As regulatory pressures increase, service providers are competing on audit-readiness, SLA precision, and pharma-centric innovation, not just speed or cost.

For instance, in February 2025, Logisteed, Ltd. opened its new Kansai Logistics Center (Kyoto Kameoka) in Kameoka City, Kyoto Prefecture. Operated by Logisteed Chemical, Ltd., the state-of-the-art facility features seven warehouses and specializes in the handling of hazardous materials. Strategically located in a major industrial area with excellent transport links, the center ensures regulatory compliance for the storage of hazardous goods across sectors, including chemicals, cosmetics, pharmaceuticals, and lithium batteries, further strengthening customer supply chains in the pharmaceutical industry.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Voice of Customers

• 5.1. Company Experience and Expertise
• 5.2. Infrastructure and Technology
• 5.3. Global Reach and Network
• 5.4. Risk Management and Insurance

6. Japan Pharmaceutical Logistics Market Outlook, FY2019-FY2033F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Type
    • 6.2.1.1. Cold Chain Logistics
    • 6.2.1.2. Non-Cold Chain Logistics
  • 6.2.2. By Procedure
    • 6.2.2.1. Picking
    • 6.2.2.2. Storage
    • 6.2.2.3. Retrieval Systems
    • 6.2.2.4. Handling Systems
  • 6.2.3. By Component
    • 6.2.3.1. Storage
    • 6.2.3.2. Transportation
    • 6.2.3.3. Monitoring Component
  • 6.2.4. By Application
    • 6.2.4.1. Chemical Pharma
    • 6.2.4.2. Biopharma
    • 6.2.4.3. Specialized Pharma
  • 6.2.5. By Operation
    • 6.2.5.1. Seaways
    • 6.2.5.2. Roadways
    • 6.2.5.3. Railways
    • 6.2.5.4. Airways
    • 6.2.5.5. Storage and Services
  • 6.2.6. By Region
    • 6.2.6.1. North
    • 6.2.6.2. Central
    • 6.2.6.3. South
  • 6.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 6.3. Market Map Analysis, FY2025
  • 6.3.1. By Type
  • 6.3.2. By Procedure
  • 6.3.3. By Component
  • 6.3.4. By Application
  • 6.3.5. By Operation
  • 6.3.6. By Region

7. Demand Supply Analysis

8. Value Chain Analysis

9. Porter's Five Forces Analysis

10. PESTLE Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Policy and Regulatory Landscape

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. A.P. MOLLER - MAERSK A/S
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. CEVA Logistics SA
  • 15.3.3. Nippon Express Co., Ltd.
  • 15.3.4. Logisteed Ltd.
  • 15.3.5. Kintetsu World Express, Inc.
  • 15.3.6. Yamato Transport Co., Ltd.
  • 15.3.7. Sagawa Express Co., Ltd.
  • 15.3.8. Yusen Logistics Co., Ltd.
  • 15.3.9. Mitsubishi Logistics Corporation
  • 15.3.10. DHL International GmbH

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Pharmaceutical Logistics Market, By Value, In USD Million, FY2019-FY2033F
• Figure 2. Japan Pharmaceutical Logistics Market Share (%), By Type, FY2019-FY2033F
• Figure 3. Japan Pharmaceutical Logistics Market Share (%), By Procedure, FY2019-FY2033F
• Figure 4. Japan Pharmaceutical Logistics Market Share (%), By Component, FY2019-FY2033F
• Figure 5. Japan Pharmaceutical Logistics Market Share (%), By Application, FY2019-FY2033F
• Figure 6. Japan Pharmaceutical Logistics Market Share (%), By Operation, FY2019-FY2033F
• Figure 7. Japan Pharmaceutical Logistics Market Share (%), By Region, FY2019-FY2033F
• Figure 8. By Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 9. By Procedure Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 10. By Component Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 11. By Application Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 12. By Operation Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 13. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025